Technology Review - Published By MIT
Advertisement
TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.
I'm a paid subscriber please
log me in
I want to purchase this article for
only $1.99
(requires login)
I want to purchase five articles for
only $7.99
(requires login)
I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

January 2005

Change of Plans, Ponce de Leon

This startup's prize is health, not youth.

By Corie Lok

Forget the fountain of youth. Although a bevy of recent scientific papers have described how to extend lab animals' life spans, the way to make money off their findings is not with drugs that prevent aging, but with ones that prevent the diseases of aging. At least that's what the founders of Sirtris Pharmaceuticals think. Spun out of Harvard University about six months ago, the company aims to translate antiaging research into medicines for diabetes.

Select from the choices above
to read the entire article.


Log In

Forgot your password?     Register »
Advertisement

Videos

Laser-Triggered Chemical Reactions
Advertisement
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2009 Technology Review. All Rights Reserved.